Radioiodine therapy in benign thyroid disorders. Evaluation of French nuclear medicine practices

Bernard, Delphine; Desruet, Marie-Dominique; Wolf, Marianne; Roux, Julie; Boin, Camille; Mazet, Roseline; Gallazzini, Céline; Calizzano, Alex; Vuillez, Jean‐Philippe; Allenet, Benoît; Fagret, Daniel

doi:10.1016/j.ando.2014.07.863

Cited by 18 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…S druge strane, u Evropi se zagovara dozimetrijski pristup (15), cilj terapije je postizanje eutireoidnog ili hipotireoidnog stanja (otklanjanje hipertireoidizma) (4), ali klinička praksa varira od zemlje do zemlje, kao i od centra do centra. Tako je u Njemačkoj dozimetrija zakonska obaveza (23,24), dok je u Francuskoj praksa u pogledu doziranja 131 I heterogena, s tim da većina centara primjenjuje fiksne doze (25,26). Istraživanje o dozimetrijskoj praksi u Evropi objavljeno 2017. godine, koje je obuhvatilo 27 zemalja i oko 20% od ukupnog broja centara u Evropi koji primjenjuju radioterapiju, pokazalo je da je terapija benignih oboljenja štitaste žlijezde pomoću 131 I najzastupljenija vrsta radioterapije i da 54% centara sprovodi indvidualno planiranje apsorbovane doze za tu vrstu terapije (27).…”

Section: Doziranje Radioaktivnog Jodaunclassified

Challenges and current views on dosing of radioactive iodine in the treatment of benign thyroid disease

Topić-Vučenović¹,

Rajkovača²,

Vezmar-Kovačević³

et al. 2017

Arhiv za farmaciju

View full text Add to dashboard Cite

Radioaktivni jod predstavlja značajnu terapijsku opciju u liječenju benignih oboljenja štitaste žlijezde. Uprkos višedecenijskom iskustvu i velikom broju liječenih pacijenata, mnoga pitanja vezana za terapiju radioaktivnim jodom još su uvijek predmet diskusija, uključujući način određivanja terapijske doze, kao i faktore koji utiču na ishod terapije. Klinička praksa, kao i preporuke odgovarajućih vodiča u pogledu doziranja radioaktivnog joda široko variraju u svijetu, od primjene fiksnih doza do kompleksnih dozimetrijskih protokola. Veća zastupljenost dozimetrijskog pristupa olakšala bi uspostavljanje korelacije doza-efekat i proučavanje uticaja raznih faktora na ishod terapije. Razvoj novih protokola za izračunavanje terapijske doze aktivnosti, kao i nova saznanja o faktorima koji utiču na ishod terapije omogućavaju dalje unaprijeđenje kako efikasnosti, tako i bezbjednosti terapije radioaktivnim jodom za individualnog pacijenta.

show abstract

Section: Doziranje Radioaktivnog Jodaunclassified

Challenges and current views on dosing of radioactive iodine in the treatment of benign thyroid disease

Topić-Vučenović¹,

Rajkovača²,

Vezmar-Kovačević³

et al. 2017

Arhiv za farmaciju

View full text Add to dashboard Cite

show abstract

“…9 It is standard practice in most institutions for physicians to prescribe empiric I-131 activities based on clinical circumstances, gland size and thyroid scintigraphy. 10,11 However, assessment of thyroid activity by scintigraphy using technetium-99m (Tc-99m) pertechnetate has been challenging due to its different kinetics and imaging characteristics to I-131. 6,12 Our institution has I-131 theranostic expertise for metastatic differentiated thyroid cancer.…”

Section: Introductionmentioning

confidence: 99%

Empiric radioiodine for hyperthyroidism: Outcomes, prescribing patterns, and its place in the modern era of theranostics

Boehm

Kao

Lai

et al. 2022

Clinical Endocrinology

View full text Add to dashboard Cite

Background The modern era of radioiodine (I‐131) theranostics for metastatic differentiated thyroid cancer requires us to rationalize the role of traditional empiric prescription in nonmalignant thyroid disease. We currently practice empiric I‐131 prescription for treatment of hyperthyroidism. This study aims to assess outcomes after treatment of hyperthyroidism by empiric I‐131 prescription at our centre, evaluate factors that impact on outcomes and prescribing practice, and gain insight into whether there is a place for theranostically‐guided prescription in hyperthyroidism. Patients and Methods A retrospective review was undertaken of all patients with Graves' disease, toxic multinodular goitre (MNG) and toxic adenoma treated with I‐131 between 2016 and 2021. Associations between clinical or scintigraphic variables and remission (euthyroid or hypothyroid) or persistence of hyperthyroidism at follow‐up were performed using standard t test as well as Pearson's product correlation. Results Of 146 patients with a mean follow‐up of 13.6 months, 80.8% achieved remission of hyperthyroidism. This was highest in toxic nodules (90.1%), compared with Graves' disease (73.8%) and toxic MNG (75.5%). In patients with Graves' disease, higher administered activity was associated with remission (p = .035). There was a weak inverse correlation between the Tc‐99m pertechnetate uptake vs prescribed activity in Graves' disease (r = −0.33; p = .009). Only one patient (0.7%) had an I‐131 induced flare of thyrotoxicosis. Conclusion Traditional empiric I‐131 prescription is a safe and effective treatment of hyperthyroidism and suitable for most patients. However, there may be a role for personalized I‐131 prescription by theranostic guidance in selected patients with high thyroid hyperactivity.

show abstract

“…Radiation is widely used in industry, medicine and science and may significantly increase uncontrolled exposure to radiation (1,2). Since the skin is the first tissue through which external radiation particles enter the human body, it is vulnerable to radiation-induced injury.…”

Section: Introductionmentioning

confidence: 99%

NF-E2-Related Factor 2 (Nrf2) Ameliorates Radiation-Induced Skin Injury

Xue

Tang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Radiation-induced skin injury (RISI) commonly occur in cancer patients who received radiotherapy and is one of the first clinical symptoms after suffering from nuclear exposure. Oxidative damage is the major causes of RISI. Nuclear factor erythroid 2-related factor 2 (Nrf2) is considered as a key mediator of the cellular antioxidant response. However, whether Nrf2 can alleviate RISI after high-dose irradiation remains unknown. In this study, we demonstrated that Nrf2-deficient (Nrf2-/-) mice were susceptible to high-dose irradiation and adenovirus-mediated overexpression of Nrf2 (ad-Nrf2) protected against radiation in skin cells. Overexpression of Nrf2 attenuated the severity of skin injury after high-dose electron beam irradiation. To uncover the mechanisms of Nrf2 involved in RISI, mRNA sequencing technology was performed to analyze the mRNA expression profiles of Ad-Nrf2 skin cells following radiation. The results revealed that a total of 127 genes were significantly changed, 55 genes were upregulated, and 72 genes were downregulated after Nrf2 overexpression. GSEA showed that Nrf2 was associated with positive regulation of genes involved in the reactive oxygen species pathway after radiation. Taken together, this study illustrated the role of Nrf2 in RISI and provided potentially strategies for ameliorating RISI.

show abstract

Radioiodine therapy in benign thyroid disorders. Evaluation of French nuclear medicine practices

Cited by 18 publications

References 17 publications

Challenges and current views on dosing of radioactive iodine in the treatment of benign thyroid disease

Challenges and current views on dosing of radioactive iodine in the treatment of benign thyroid disease

Empiric radioiodine for hyperthyroidism: Outcomes, prescribing patterns, and its place in the modern era of theranostics

NF-E2-Related Factor 2 (Nrf2) Ameliorates Radiation-Induced Skin Injury

Contact Info

Product

Resources

About